CEBPA双等位基因突变急性髓系白血病:协同病变、分子机制与临床意义
本文综述CEBPA双等位基因突变急性髓系白血病中协同突变的研究进展,探讨这些病变与CEBPA突变的合作模式、潜在分子机制及其对疾病生物学和临床结局的影响,并讨论个性化医疗的未来选择。
要点
- CEBPA双等位基因突变AML已被WHO分类列为独立疾病实体。
- CEBPA突变常与其他遗传学异常共存,共同构成白血病的克隆层级。
- 协同突变的模式与分子机制影响疾病生物学和患者临床结局。
核心结论
- CEBPA双等位基因突变AML中协同突变塑造克隆层级,影响疾病生物学与临床结局,为个性化医疗提供依据。
研究设计与样本
- 综述性文章,基于测序技术进展总结CEBPA突变AML中协同突变的研究现状。
主要发现
- CEBPA突变在AML中频繁发生,双等位基因突变被WHO分类认定为独立疾病实体。
- CEBPA突变与其他遗传学异常共存,共同构成患者的白血病克隆层级。
- 综述重点讨论协同突变的模式、与CEBPA突变的合作方式及潜在分子机制。
临床怎么用
- 临床应关注CEBPA双等位基因突变AML患者的协同突变谱,以评估疾病生物学和预后。
- 协同突变信息可为未来个性化治疗策略的选择提供参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent advances in sequencing technologies have allowed for the identification of recurrent mutations in acute myeloid leukaemia (AML). The transcription factor CCAAT enhancer binding protein alpha (CEBPA) is frequently mutated in AML, and biallelic CEBPA-mutant AML was recognised as a separate disease entity in the recent World Health Organization classification. However, CEBPA mutations are co-occurring with other aberrations in AML, and together these lesions form the clonal hierarchy that comprises the leukaemia in the patient. Here, we aim to review the current understanding of co-occurring mutations in CEBPA-mutated AML and their implications for disease biology and clinical outcome. We will put emphasis on patterns of cooperation, how these lesions cooperate with CEBPA mutations and the underlying potential molecular mechanisms. Finally, we will relate this to patient outcome and future options for personalised medicine.
引用
- Wilhelmson AS, Porse BT. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance. Br J Haematol. 2020. PMID: 32086816. doi:10.1111/bjh.16534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。